Meeting
2017 Genitourinary Cancers Symposium
Evaluation of the clinical activity of ipilimumab (IPI) plus nivolumab (NIVO) in patients (pts) with NIVO-refractory metastatic urothelial cancer (UC).
Authors
Margaret K. Callahan
Memorial Sloan Kettering Cancer Center, New York, NY
Margaret K. Callahan , Brooke Elizabeth Kania , Gopa Iyer , Jessica Mary Clement , Samuel Funt , Asia S. McCoy , Grace Hettich , Etay Ziv , Mark J. Bluth , Phillip Wong , Jedd D. Wolchok , Dean F. Bajorin , Jonathan E. Rosenberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT02553642
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 384)
DOI
10.1200/JCO.2017.35.6_suppl.384
Abstract #
384
Poster Bd #
H21
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2023 ASCO Annual Meeting
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
First Author: Scott N. Gettinger
Poster
2020 ASCO Virtual Scientific Program
Combination immunotherapy with ipilimumab and nivolumab in patients with rare gynaecological malignancies.
First Author: Oliver Klein
Poster
2018 Genitourinary Cancers Symposium
A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SOC) versus SOC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
First Author: Matt D. Galsky